PRL3 ZUMAB

Drug Profile

PRL3 ZUMAB

Alternative Names: PRL3-ZUMAB

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INTRA-IMMUSG
  • Developer INTRA-IMMUSG; National University Hospital (Singapore)
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Prolactin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 22 Jun 2017 Pharmacodynamics data from a preclinical trial in Solid tumours released by INTRA-IMMUSG
  • 20 Feb 2017 Phase-I clinical trials in Solid tumours (Metastatic disease, In adults, In the elderly, Late-stage disease, Inoperable/Unresectable) in Singapore (IV) (NCT03191682)
  • 16 Jun 2016 Preclinical trials in Solid tumours in Singapore (IV) before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top